Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Commissioner Changes Could Impact Pharma Mergers, Scrutiny Of Biosimilars Uptake

Executive Summary

President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.

You may also be interested in...



Divided FTC Okays Mylan-Upjohn Merger But Election Outcome Could Impede Future Deals

Commissioners vote 3-2 that Mylan and Pfizer’s Upjohn can combine after divesting seven products; dissenting votes focus on price fixing allegations as commissioners Chopra and Slaughter criticize majority for not addressing government’s case against Pfizer and Mylan. Former FTC attorneys note that if Biden wins the presidential election, he could nominate one of the dissenters to FTC chair and give more traction to their views.

AndroGel $448M Pay-For-Delay Disgorgement Spiked On Appeal, But Some Of FTC Complaint Resurrected

AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.

Indivior Must Disband Suboxone Sales Force, Implement Executive Pay Recoupment Program

$600m settlement with DOJ over Suboxone marketing includes corporate integrity agreement and exclusion of subsidiary from government health programs. Indivior also agrees to pay $10m to FTC and be enjoined from future antitrust violations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel